Gynecology

Welcome Message

Session & Tracks

Track 1: Surgical Innovations in Gynecology

Track 2: Reproductive Health and Fertility

Track 3: Women's Wellness and Preventive Care

Track 4: Advances in Obstetrics and Maternal-Fetal Medicine

Track 5: Hormonal Health and Menopause Management

Track 6: Pelvic Floor Disorders and Urogynecology

Track 7: Infectious Diseases and STI Prevention

Track 8: Genetics and Genomic Medicine in Women Health

Track 9: Mental Health and Psychosocial Aspects of Women Health

Track 10: Ethics, Law, and Policy in Women Healthcare

Why to Attend?

Business networking opportunities abound, providing vendors with avenues for B2B meetings with top scientists and colleagues. This serves as an effective, low-cost marketing method for developing sales and forging valuable contacts.

Join us in Madrid for an enriching experience where knowledge converges, innovation thrives, and the future of gynecological care is shaped.

2024 Highlights:

• 150 Participation (70 Industry: 30 Academia)
• 10+ Keynote Speakers
• 50+ Plenary Speakers
• 05+ Exhibitors
• 12 Innovative Educational Sessions
• 5+ Workshops

Benefits of Attending

• To foster discussions, share expertise and exchange knowledge and best practices at all levels of the healthcare spectrum
• To encourage collaboration and enhance interactions at a global level
• Meet a range of specialists actively practicing in the field
• Strengthen your profile and position your organization as a key industry figure
• Develop new partnerships and networks with key decision makers/influencers
• Open doors for your organization to connect and develop strategic relationships in a neutral and relaxed sales environment
• Get access to targeted audience
• Brand Exposure – Promote your company’s message, products and services through a national Conference marketing campaign
• First hand live demonstrations to delegates
• To showcase new healthcare technologies and solutions in an intimate setting focused specifically on gynecology.

Targeted Audience

• Directors, CEO’s of Organizations
• Business Development Managers
• Chief Scientific Officers
• R&D Researchers from Pharma Industries
• Professors, Associate Professors, Assistant Professors
• PhD Scholars
• Association, Association presidents and professionals
• Noble laureates in Health Care and Medicine
• Research Institutes and members
• Manufacturing Companies
• Training Institutes

Market Analysis

The global gynecology market is experiencing steady growth, fueled by increasing disease prevalence, technological advancements, and a growing emphasis on preventive care. Technological innovations, including advanced imaging and minimally invasive procedures, enhance patient outcomes. Rising awareness of women's health issues drives demand for gynecological services, while emerging markets offer untapped opportunities. However, challenges such as healthcare disparities and regulatory complexities persist. Collaborative efforts are crucial for addressing these challenges and ensuring equitable access to quality gynecological care. Overall, the gynecology market remains dynamic, with significant potential for expansion and advancements in women's health globally. 

Gynecology Drugs Market Analysis

The gynecology drugs market is projected to grow at a 6.2% CAGR.

• Initial impact of COVID-19 slowed market growth due to diverted resources and lockdowns.
• Drivers include increasing burden of gynecological diseases, rising healthcare awareness, and aging female  population.
• Continued rise in gynecological diseases, like PCOS and cancers, expected to drive market demand.
• In 2022, around 14,100 new cervical cancer cases and 19,880 ovarian cancer diagnoses were reported in the US.
• Market growth is further fueled by developments like Myovant Sciences and Pfizer's MYFEMBREE approval for managing heavy menstrual bleeding.
• Challenges such as high costs and stringent regulations may hinder market growth.

Gynecology Drugs Market Trends

• Non-hormonal Therapy Segment Set for High Growth
• Expect significant growth in the non-hormonal therapy segment.
• Reasons include proven effectiveness, fewer side effects in new product development, and a wide range of available options.
• Drawbacks of hormonal therapy, like breast cancer risk, boost demand for non-hormonal products.
• Studies show potential benefits, like suppressing ovarian endometriosis and improving ovarian function.
• Increasing clinical trials, like Bayer's OASIS program for menopausal symptoms, drive segment growth.
• This trend raises awareness of non-hormonal therapy for gynecological cancers, promising substantial growth ahead.

North America is expected to hold a Significant Share in the Gynecology Drugs Market

• North America's Strong Presence in Gynecology Drugs Market
• North America poised to dominate gynecology drugs market due to increasing cases of breast cancer, menopausal disorders, and polycystic ovary syndrome.
• Factors contributing to dominance include advanced healthcare infrastructure, government initiatives for women's health, and early high-quality product launches.
• Key drivers of market growth in the region include significant product launches, concentration of market players, and partnerships.
• High prevalence of gynecological cancers in the United States, such as breast cancer, expected to drive demand for gynecology drugs, fueling market growth.

Analyze Key Geographic Markets

Leading Companies in the Gynecology Drugs Market:

1. Ferring Holding SA
2. TherapeuticsMD Inc.
3. AbbVie Inc.
4. Pfizer Inc.
5. GSK plc

In summary, the gynecology drugs market shows robust growth potential despite COVID-19 disruptions. Factors like increasing disease burden and the shift towards non-hormonal therapies drive expansion. North America leads due to advanced healthcare infrastructure and high disease prevalence. Key players, including Ferring Holding SA and Pfizer Inc., are well-positioned to capitalize on market opportunities through innovation and strategic partnerships. Despite challenges, the market outlook remains optimistic, with steady growth expected.

Source: https://www.mordorintelligence.com/industry-reports/gynecology-drugs-market